Manufacture of inter-alpha-inhibitor (IaIp) from plasma
View Patent ↗The present invention provides compositions and pharmaceutical formulations of IaIp derived from plasma. Also provided are methods for the manufacture of the IaIp compositions and formulations, as well as method for the treatment of diseases associated with IaIp dysfunction.
1. A method for preparing an enriched Inter-alpha-Inhibitor protein (IaIp) composition from plasma, the method comprising the steps of:
(a) providing a Cohn pool;
(b) precipitating IaIp from the Cohn pool in at least a first ethanol precipitation reaction to form an IaIp-containing precipitate; and
(c) extracting IaIp from the IaIp-containing precipitate, thereby forming an enriched IaIp composition;
wherein the IaIp-precipitate is selected from the group consisting of a Fraction I precipitate, a Fraction I+II+III precipitate, or a Fraction II+III precipitate:
wherein the Fraction I precipitate is prepared by:
(i) precipitating IaIp from a Cohn pool, in a first precipitation step, with between about 6% and about 10% alcohol at a pH of between about 7.0 and about 7.5 to form a first precipitate,
wherein the Fraction II+III precipitate is prepared by:
(i) precipitating IaIp from a Cohn pool, in a first precipitation step, with between about 6% and about 10% alcohol at a pH of between about 7.0 and about 7.5 to obtain a first precipitate and a first supernatant; and
(ii) precipitating IaIp from the first supernatant, in a second precipitation step, with between about 20% and about 25% alcohol at a pH of between about 6.7 and about 7.3 to form a second precipitate, or
wherein the Fraction I+II+III precipitate is prepared by:
(i) precipitating IaIp from a Cohn pool, in a first precipitation step, with between about 15% and about 25% alcohol at a pH of between about 6.5 and about 7.5 to form a first precipitate.
2. The method of claim 1 , wherein IaIp is extracted from both a Fraction I precipitate and a Fraction II+III precipitate formed during a single Cohn plasma fractionation.
3. The method of claim 1 , further comprising the step of:
(d) precipitating impurities from the enriched IaIp composition, in an additional precipitation step, thereby forming a supernatant containing IaIp.
4. The method of claim 3 , wherein the additional precipitation step comprises precipitation with between about 10% and about 19% alcohol at a pH of between about 6.0 and about 8.0.
5. The method of claim 1 , wherein at least one of the precipitation steps comprises spray addition of alcohol.
6. The method of claim 5 , wherein all of the precipitation steps comprise spray addition of alcohol.
7. The method of claim 1 , wherein the enriched IaIp composition is further subjected to at least one viral inactivation step.
8. The method of claim 7 , wherein the viral inactivation step comprises treatment with a solvent and/or detergent, nanofiltration, heat treatment, or incubation at low pH.
9. The method of claim 1 , wherein a single Inter-alpha-Inhibitor protein (IaIp) species is isolated.
10. The method of claim 9 , wherein the IaIp species is Inter-alpha-Trypsin Inhibitor (IaI).
11. The method of claim 9 , wherein the IaIp species is Pre-alpha-Inhibitor (PaI).
12. The method of claim 9 , wherein the IaIp species is isolated by an antibody affinity method.
13. The method of claim 1 , wherein the pH of the solution is modified after the addition of alcohol in at least one precipitation step by the addition of a pH modifying agent.
14. The method of claim 13 , wherein the addition of a pH modifying agent comprises the spray addition of a pH modifying solution.
15. The method of claim 1 , wherein the pH of a precipitation step is modified before and after the addition of alcohol, during and after the addition of alcohol, or before, during, and after the addition of alcohol.
16. The method of claim 1 , wherein the pH of a precipitation step is maintained for the entire precipitation step by continuous adjustment of the pH.
17. The method of claim 3 , further comprising the step:
(e) precipitating IaIp, in an additional precipitation step.
18. The method according to claim 17 , wherein IaIp is precipitated with between about 20% and about 25% alcohol at a pH of between about 6.0 and about 8.0.
19. The method of claim 17 , further comprising the steps of:
(f) binding IaIp from the enriched IaIp composition to an anion exchange resin; and
(g) eluting the IaIp from the anion exchange resin with an elution buffer, thereby forming a first eluate containing IaIp.
20. The method of claim 19 , further comprising the steps of:
(h) binding IaIp from the first eluate to a heparin affinity resin; and
(i) eluting the IaIp from the heparin affinity resin with an elution buffer, thereby forming a second eluate containing IaIp.
21. The method of claim 20 , wherein the IaIp present in either the first or second eluate is further enriched.
22. The method of claim 1 , wherein the IaIp-precipitate is a Fraction I precipitate prepared by:
(i) precipitating IaIp from a Cohn pool, in a first precipitation step, with between about 6% and about 10% alcohol at a pH of between about 7.0 and about 7.5 to form a first precipitate.
23. The method of claim 1 , wherein the IaIp-precipitate is a Fraction II+III precipitate prepared by:
(i) precipitating IaIp from a Cohn pool, in a first precipitation step, with between about 6% and about 10% alcohol at a pH of between about 7.0 and about 7.5 to obtain a first precipitate and a first supernatant; and
(b) precipitating IaIp from the first supernatant, in a second precipitation step, with between about 20% and about 25% alcohol at a pH of between about 6.7 and about 7.3 to form a second precipitate.
24. The method of claim 1 , wherein the IaIp-precipitate is a Fraction I+II+III precipitate prepared by:
(i) precipitating IaIp from a Cohn pool, in a first precipitation step, with between about 15% and about 25% alcohol at a pH of between about 6.5 and about 7.5 to form a first precipitate.